BLAINJECTIONINJECTABLE
Approved
Aug 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
4/8 — Partial
PAVBLU (aflibercept-ayyh) by Amgen is vascular endothelial growth factor inhibitors [moa]. Approved for vascular endothelial growth factor inhibitor [epc]. First approved in 2024.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PAVBLU (aflibercept-ayyh) is a biosimilar fusion protein that inhibits vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), used to treat neovascular (wet) age-related macular degeneration and other retinal conditions. It works by binding VEGF and PlGF to prevent abnormal blood vessel growth in the eye. This Amgen-sponsored product represents a competitive entry into the established anti-VEGF therapeutic class.
Growth
Early-stage growth product with moderate competitive pressure (30%) suggests expanding commercial infrastructure and field team opportunity.
Mechanism of Action
Vascular Endothelial Growth Factor Inhibitors
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on PAVBLU at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.